Ohana Development發布「Jacob & Co. Beachfront Living by Ohana」住宅社區——阿聯優雅海濱傑作

阿拉伯聯合大公國阿布達比--(BUSINESS WIRE)--(美國商業資訊)-- 以豪華住宅馳名的領先房地產開發商Ohana Development與奢華鐘錶和珠寶品牌Jacob & Co.合作推出「Jacob & Co. Beachfront Living by Ohana」住宅社區，並於阿布達比Emirates Palace Mandarin Oriental酒店揭幕。該專案位於杜拜和阿布達比之間的Al Jurf，耗資13億美元，是自然環境與卓越藝術和工藝的完美融合。
Jacob & Co. Beachfront Living by Ohana共有457套住宅，包括海景公寓、別墅、頂樓公寓、空中豪宅和海濱豪宅，每套住宅皆體現了精緻海濱生活精神。頂樓公寓起價600萬美元，坐擁180度景觀和寬敞的室內空間，空中豪宅起價2,100萬美元，享有360度全景視野和私人專用電梯。
可客製的3至6房別墅和豪宅均配有私人泳池，自然保護區或運河景觀盡收眼底，而海濱豪宅則擁有無與倫比的空間和無敵海景。
Ohana Development執行長Husein Salem表示：「我們對Jacob & Co. Beachfront Living by Ohana的願景是，沿海岸線開發獨一無二的居住聖地，提升海濱生活體驗。我們致力於打造一個海濱天堂，精緻體驗、經典優雅與寧靜祥和在這裡匯聚，為人們提供一種與眾不同的生活方式。」
Jacob & Co.董事長暨創意總監Jacob Arabo補充道：「我們與Ohana Development緊密合作，將我們卓越的藝術傳統和超豪華生活方式融入每一個細節。Jacob & Co. Beachfront Living by Ohana是對海岸藝術的致敬，在這裡，設計、工藝和大海的魅力融為一體，創造出非凡的家園。」
度假風格設施包括配備全球首個品牌海濱雪茄酒廊的Jacob & Co. Social Club、商務中心和會員制Jacob & Co. Residents Club，俱樂部內設有鐘錶展廳，並定期舉辦藝術展覽。該住宅區也推出了全球首個活力海濱專案——Jacob & Co. Beach Club。
住戶甫一抵達，所走進的宏偉入口中庭頂端鑲嵌有一個10米寬的Jacob & Co.天花板藝術鐘錶。該鐘錶計劃於2028年第二季完工。
如需瞭解更多資訊，請造訪： https://ohana-development.com 。
免責聲明：本公告之原文版本乃官方授權版本。譯文僅供方便瞭解之用，煩請參照原文，原文版本乃唯一具法律效力之版本。

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

Business Wire

an hour ago

• Business Wire

Exelixis Announces Zanzalintinib in Combination with an Immune Checkpoint Inhibitor Improved Overall Survival in STELLAR-303 Phase 3 Pivotal Trial in Patients with Metastatic Colorectal Cancer

BUSINESS WIRE)-- Exelixis, Inc. (Nasdaq: EXEL) today announced positive topline results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with atezolizumab (Tecentriq ®) demonstrated a statistically significant improvement in overall survival (OS) versus regorafenib in the intent-to-treat (ITT) population of patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). These topline findings are from the final analysis conducted by the Independent Data Monitoring Committee of one of the dual primary endpoints of the STELLAR-303 phase 3 trial. The trial will proceed to the planned final analysis for the other dual primary endpoint of OS in patients without liver metastases (non-liver metastases, NLM). The safety profiles of zanzalintinib in combination with atezolizumab and of regorafenib were generally consistent with what has been previously observed, and no new safety signals were identified. The ITT population consisted of all randomized patients, regardless of the presence of liver metastases. The NLM subgroup consisted of patients who did not have active liver metastases at baseline as determined by investigator assessment. 'The STELLAR-303 results, which showed a survival benefit with the combination of zanzalintinib and atezolizumab versus regorafenib across all randomized patients with previously treated metastatic colorectal cancer, marks an important first milestone for our zanzalintinib pivotal development program,' said Amy Peterson, M.D., Executive Vice President, Product Development & Medical Affairs, and Chief Medical Officer, Exelixis. 'We look forward to discussing the findings with regulatory authorities and presenting the detailed results at an upcoming medical conference.' Secondary endpoints of STELLAR-303 include progression-free survival, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. Exelixis plans to submit detailed results of STELLAR-303 for presentation at an upcoming medical conference. About STELLAR-303 STELLAR-303 (NCT05425940) is a global, multicenter, randomized, phase 3, open-label study that randomized 901 patients 1:1 to either zanzalintinib (100 mg) in combination with atezolizumab or regorafenib. The study includes patients with previously treated non-MSI-high metastatic CRC. The dual primary endpoints of the study are OS in the ITT population and in the NLM subgroup of patients. Presence of liver metastases at baseline for all enrolled patients was determined by investigator assessment. Secondary endpoints include progression-free survival, objective response rate and duration of response in the ITT population and in the NLM subgroup of patients. More information about the trial is available at About Zanzalintinib Zanzalintinib is a third-generation oral tyrosine kinase inhibitor that inhibits the activity of receptor tyrosine kinases implicated in cancer growth and spread, including VEGF receptors, MET, AXL and MER. These receptor tyrosine kinases are involved in both normal cellular function and in pathologic processes such as oncogenesis, metastasis, tumor angiogenesis and resistance to multiple therapies, including immune checkpoint inhibitors. With zanzalintinib, Exelixis sought to build upon its extensive experience with the target profile of cabozantinib, the company's flagship medicine, while improving key characteristics, including pharmacokinetic half-life. Zanzalintinib is currently being developed for the treatment of advanced solid tumors, including colorectal cancer, kidney cancer, head and neck cancer and neuroendocrine tumors. Zanzalintinib is an investigational agent that is not approved for any use and is the subject of ongoing clinical trials. About CRC CRC is the third most common cancer and the second leading cause of cancer-related deaths in the U.S. 1 Approximately 154,000 new cases will be diagnosed in the U.S. with around 53,000 expected deaths from the disease in 2025. 1 CRC is most frequently diagnosed among people aged 65-74 and is more common in men and in people of non-Hispanic American Indian/Alaska Native descent. 2 Nearly a quarter of CRC cases are diagnosed at the metastatic stage, at which point the five-year survival rate is just 16.2%. 2 The liver is the most common site for CRC metastasis. Liver metastases significantly impact survival, with a median five-year survival rate of less than 14% when treated with palliative chemotherapy. 3 About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug discovery and development excellence, we are rapidly evolving our product portfolio to target an expanding range of tumor types and indications with our clinically differentiated pipeline of small molecules, antibody-drug conjugates and other biotherapeutics. This comprehensive approach harnesses decades of robust investment in our science and partnerships to advance our investigational programs and extend the impact of our flagship commercial product, CABOMETYX ® (cabozantinib). Exelixis is driven by a bold scientific pursuit to create transformational treatments that give more patients hope for the future. For information about the company and its mission to help cancer patients recover stronger and live longer, visit follow @ExelixisInc on X (Twitter), like Exelixis, Inc. on Facebook and follow Exelixis on LinkedIn. Forward-Looking Statements This press release contains forward-looking statements, including, without limitation, statements related to: the therapeutic potential of the combination of zanzalintinib in combination with atezolizumab to improve overall survival in patients with metastatic CRC; Exelixis' plans to discuss the trial data from STELLAR-303 with regulatory authorities and to present detailed findings at an upcoming medical conference; and Exelixis' scientific pursuit to create transformational treatments that give more patients hope for the future. Any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements and are based upon Exelixis' current plans, assumptions, beliefs, expectations, estimates and projections. Forward-looking statements involve risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in the forward-looking statements as a result of these risks and uncertainties, which include, without limitation: the availability of data at the referenced times; complexities and the unpredictability of the regulatory review and approval processes in the U.S. and elsewhere; Exelixis' continuing compliance with applicable legal and regulatory requirements; unexpected concerns that may arise as a result of the occurrence of adverse safety events or additional data analyses of clinical trials evaluating zanzalintinib; Exelixis' dependence on third-party vendors for the development, manufacture and supply of zanzalintinib; Exelixis' ability to protect its intellectual property rights; market competition; changes in economic and business conditions; and other factors affecting Exelixis and its development programs detailed from time to time under the caption 'Risk Factors' in Exelixis' most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q, and in Exelixis' future filings with the Securities and Exchange Commission. All forward-looking statements in this press release are based on information available to Exelixis as of the date of this press release, and Exelixis undertakes no obligation to update or revise any forward-looking statements contained herein, except as required by law. Exelixis, the Exelixis logo and CABOMETYX are registered U.S. trademarks of Exelixis. TECENTRIQ is a registered U.S. trademark of Genentech, a member of the Roche Group. ___________________________ 1 Key Statistics for Colorectal Cancer. ACS website. Available at: Accessed June 2025. 2 Cancer Stat Facts: Colorectal Cancer. SEER website. Available at: Accessed June 2025. 3 Ros J, Salva F, Dopazo C, et al. Liver transplantation in metastatic colorectal cancer: are we ready for it? Br J Cancer. May 2023;128(10):1797-1806.

Time Business News

8 hours ago

• Time Business News

Meet&Co Office Furniture Wholesaler: Trusted Partner for Modern Workspaces

In today's rapidly evolving business landscape, the design and functionality of office spaces play a crucial role in productivity, collaboration, and overall employee satisfaction. Businesses worldwide are shifting toward modern workspaces—open, modular, ergonomic, and inspiring. At the core of this transformation is Meet&Co, a globally trusted office furniture wholesaler renowned for its innovative designs, quality craftsmanship, and full-service approach. Whether you're a startup founder, interior designer, procurement officer, or enterprise-level decision-maker, this guide will help you understand why Meet&Co is the ideal partner to furnish your modern workspace efficiently and affordably. Meet&Co is a China-based office furniture manufacturer and wholesaler, with over a decade of experience delivering stylish, ergonomic, and scalable office furniture to clients worldwide. Known for their reliability and ability to handle bulk orders, Meet&Co has become a household name in B2B office furnishings, serving corporations, resellers, coworking spaces, and educational institutions across more than 100 countries. Key facts about Meet&Co: Headquarters: Guangzhou, China Founded: 2011 Service Reach: Over 100 countries Product Range: Office desks, chairs, workstations, conference tables, storage, and lounge furniture Core Values: Innovation, Integrity, Customization, and Customer Satisfaction Buying wholesale isn't just about getting better prices—it's about scale, consistency, and long-term value. Here's why sourcing from a wholesale supplier like Meet&Co is a smart business decision: Meet&Co offers competitive pricing for bulk orders, which is essential for startups, real estate developers, and companies outfitting entire office buildings. Wholesale partnerships allow businesses to expand or reconfigure spaces easily without design inconsistencies or availability issues. Wholesale suppliers often offer customization. Meet&Co, for instance, tailors finishes, sizes, and upholstery to match your brand's aesthetic. With logistics partners across continents, Meet&Co ensures on-time delivery and smooth customs processes for international clients. Meet&Co isn't just a furniture supplier—it's a strategic workspace partner. Here's what sets them apart: From design consultation to delivery and installation, Meet&Co covers every step of the office furnishing process. They understand cultural nuances and work requirements across different regions, making them ideal for multinational companies. Advanced manufacturing and a highly organized supply chain enable faster production and delivery. Clients receive dedicated managers to oversee their project from planning to post-installation support. Meet&Co's catalog is designed for modern functionality while maintaining professional aesthetics. Here's an in-depth look: Modern, sleek, and highly functional—these desks combine storage, wire management, and premium materials. Ideal for leadership offices. From task chairs to high-end executive seating, all chairs are ergonomic, BIFMA-certified, and available in mesh, leather, or fabric. Workstations Open-plan modular systems with privacy panels, cable management, and flexibility for team configurations. Available in various shapes (rectangular, boat-shaped, modular) with built-in power sockets and durable surfaces. First impressions matter. Meet&Co's reception units are modern, welcoming, and often customizable with branding. Lockable filing cabinets, credenzas, mobile pedestals, and shelving that blend seamlessly with office aesthetics. Office sofas, breakout seating, and coffee tables designed for comfort, collaboration, and informal meetings. Meet&Co understands that one size doesn't fit all. Their team of in-house designers collaborates with clients to create furniture that reflects a company's brand and culture. Custom options include: Desk shapes and sizes Materials and surface finishes Upholstery and chair configurations Storage layout and function Color matching with brand palettes They also offer 3D layout rendering services, enabling clients to visualize how furniture will fit into their floor plan. Meet&Co is committed to sustainable manufacturing, adhering to global environmental standards: Use of low-emission adhesives and finishes FSC-certified wood sourcing Waste reduction in production processes Eco-friendly packaging options Long product lifespans and recyclability For businesses prioritizing green offices, Meet&Co is an ideal partner aligned with LEED and WELL building certification goals. Meet&Co has shipped office furniture to businesses in the USA, Canada, Australia, UAE, UK, South Africa, and more. Multi-language support Documentation for customs Ocean and air freight options Regional warehousing partnerships After-sales service guarantees They work closely with B2B partners such as: Furniture resellers Interior design firms Facility management companies Corporate procurement teams 'Meet&Co provided full furnishing for our three-floor coworking space in Dubai. Their quality and turnaround time were exceptional.' — Hassan K., Project Manager, UrbanSpace MENA 'As a reseller in Canada, we trust Meet&Co for every bulk project. Their logistics, support, and consistency are unmatched.' — Lauren M., Founder, FurniBulk Canada 'We needed modern furniture for 120 employees. Meet&Co handled it from design to install and stayed under budget.' — Emilio R., Admin Head, TechEdge Europe Feature Meet&Co Other Wholesalers Global Shipping ✔ Yes ⚠ Varies by region Customization ✔ Extensive Options ⚠ Limited Design Consultation ✔ Included ❌ Often extra cost Sustainability Standards ✔ High (FSC, BIFMA) ⚠ Not always disclosed MOQ (Minimum Order Qty) ✔ Flexible ⚠ High minimums common Price Transparency ✔ Quotation system ⚠ Hidden fees possible Getting started with Meet&Co is straightforward: Browse the Catalog at Meet&Co's official website Submit a Request for Quotation (RFQ) Consult with a Project Manager about your needs Receive 3D Layouts and Samples if needed Confirm Customizations and finalize pricing Production Begins (typically 15–30 days) Shipping & Installation Support provided After-Sales Support available globally Whether you're furnishing a startup office, equipping an enterprise HQ, or looking for a reliable B2B partner, Meet&Co Office Furniture Wholesaler delivers modern, functional, and beautifully designed solutions. With a commitment to quality, customization, global support, and sustainable practices, Meet&Co stands out as a true trusted partner for modern workspaces. Answer: MOQ depends on the product category, but Meet&Co is flexible for startups and small businesses. Answer: Yes. Meet&Co has shipped to over 100 countries with reliable freight partners. Answer: Yes. They offer free 3D layout and space planning services with every project. Answer: Typically 15–30 days for production and 10–25 days for shipping, depending on location. Answer: Products are BIFMA and ISO-certified, and wood materials are often FSC-approved. TIME BUSINESS NEWS

Business Wire

18 hours ago

• Business Wire

2025 Zhejiang (Egypt) International Engineering Exhibition Successfully Held

RIYADH, Saudi Arabia & CAIRO--(BUSINESS WIRE)--From June 17th to 19th, 2025, the Zhejiang (Egypt) International Engineering Exhibition was successfully held in Hall 3 of the Cairo International Exhibition Center. Hosted by the Department of Commerce of Zhejiang Province and organized by the Zhejiang International Contractors Association and Hangzhou Boheng Business Exhibition Co., Ltd., the exhibition was held alongside the prominent 2025 Egypt Big 5 Construction Show. Zhejiang showcased its unified provincial image through a dedicated area featuring 10 enterprises, 15 representatives, and an exhibition space of 108 square meters. Participating companies included Yoking Pump Co., Ltd., Zhitao Electric Group Co., Ltd., Zhejiang Qiankai Electric Equipment Co., Ltd., and Hangzhou Fulltime Robotics Co., Ltd. Over three days, Zhejiang enterprises interacted with more than 920 professional merchants from 12 countries and regions, resulting in intended transaction amounts of $5.7 million. Strategically located at the crossroads of Asia, Africa, and Europe, Egypt plays a key role in the Belt and Road Initiative. In May 2024, China and Egypt signed the Cooperation Plan on Jointly Promoting the Construction of the Belt and Road Initiative, which defined key cooperation areas. This strengthened framework will deepen collaboration and fuel development. To diversify its economy, Egypt has initiated projects like 'Egypt Vision 2030,' the New Administrative Capital, and the Suez Canal Corridor—sectors with strong demand for construction and renewable energy. These developments open new avenues for Zhejiang enterprises to participate in Egypt's infrastructure upgrades. Zhejiang Province has been advancing its 'Sweet Potato Economy' strategy to upgrade the 'No. 1 Opening-Up Project.' In 2024, newly signed foreign contracting projects totaled $5.486 billion (up 11.57%), with a completed turnover of $7.995 billion (up 15.27%), ranking fourth nationwide in business scale. This Egyptian exhibition marked Zhejiang's first self-organized overseas event in 2025. Themed 'Shaping a Smart, Green Future with Zhejiang,' it underscored the province's capabilities in green technology and smart construction. Zhejiang will continue to leverage overseas exhibitions to help more enterprises expand globally, foster cooperation and technology exchange, and offer sustainable solutions to global engineering challenges.